Search results
Showing 16 to 30 of 103 results for bladder cancer
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
Status ...
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer
Register an interest in this interventional procedure ...
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.
This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS90Show all sections
Sections for QS90
- Quality statements
- Quality statement 1: Diagnosing urinary tract infections in women under 65
- Quality statement 2: Diagnosing urinary tract infections in adults with catheters
- Quality statement 3: Antibiotic treatment for asymptomatic bacteriuria in men and non-pregnant women
- Quality statement 4: Duration of antibiotic treatment for urinary tract infection
- Quality statement 5: Referring adults with recurrent urinary tract infection
- Update information
- About this quality standard
satisfaction for bladder cancer? Any explanatory notes(if applicable) The urological cancers grouping (which includes...
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]
Awaiting development [GID-TA11115] Expected publication date: TBC
of intravesical chemotherapy (IVCT) following transurethral resection of bladder tumour (TURBT) has been shown to decrease the risk of...
Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?...
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development [GID-TA11300] Expected publication date: TBC
Awaiting development [GID-TA11469] Expected publication date: TBC
Awaiting development [GID-TA11556] Expected publication date: TBC
Awaiting development [GID-TA11336] Expected publication date: TBC
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.